Credit: ©2012, Mary Ann Liebert, Inc., publishers
New Rochelle, NY, May 20, 2019–A comprehensive new review of the expanding scope of stimulants available to treat attention deficit hyperactivity disorder (ADHD) serves as a valuable guide to clinicians as they choose from among the many new drug formulations and technologies available to treat this complex disorder. The wide-ranging review is published in the Journal of Child and Adolescent Psychopharmacology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. Click here to read the full-text article free on the Journal of Child and Adolescent Psychopharmacology website through June 20, 2019.
Entitled “New Formulations of Stimulants: An Update for Clinicians,” the article was coauthored by Ronald Steingard, MD, Child Mind Institute (New York, NY), Sarper Taskiran, MD, Child Mind Institute and Koc University School of Medicine (Istanbul, Turkey), Mark Stein, PhD, University of Washington (Seattle), Daniel Connor, MD, University of Connecticut School of Medicine (Farmington), and John Markowitz, PharmD, University of Florida (Gainesville).
Th manuscript is designed to provide a guide to newer stimulant formulations. Following a brief review of ADHD and the two most common stimulants used for treatment – amphetamine and methylphenidate — the authors focus on the rapid growth in new formulations of these drugs. They explain novel delivery systems such as orally dissolving tablets (ODT), chewable tablets, extended release (ER) liquid formulations, transdermal patches, and novel “beaded” technology and suggest how to use them in clinical practice. In addition, the authors look at the advances in our knowledge regarding individual variability with regards to response and metabolism that has contributed to a more nuanced approach to treatment.
Harold S. Koplewicz, MD, Editor-in-Chief of the Journal of Child and Adolescent Psychopharmacology and President of the Child Mind Institute in New York, states: “‘New Formulations of Stimulants: An Update for Clinicians,’ written by Ron Steingard, MD and colleagues is an essential guide for pediatricians, pediatric neurologists, and child and adolescent psychiatrists who treat children and teens with ADHD.”
About the Journal
Journal of Child and Adolescent Psychopharmacology is an authoritative peer-reviewed journal published bimonthly in print and online. The Journal is dedicated to child and adolescent psychiatry and behavioral pediatrics, covering clinical and biological aspects of child and adolescent psychopharmacology and developmental neurobiology. Complete tables of content and a sample issue may be viewed on the Journal of Child and Adolescent Psychopharmacology website.
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Cyberpsychology, Behavior, and Social Networking, Games for Health Journal, and Violence and Gender. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.